SeaStar Medical Holding Corp (ICU) Form 8-K — May 13, 2026
SeaStar Medical Holding Corporation reported a 69% increase in first quarter revenue to $0.5 million, driven by the addition of 7 top-rated children’s hospitals to its QUELIMMUNE® pediatric acute kidney injury (AKI) customer base. The company advanced enrollment in the NEUTRALIZE-AKI pivotal trial, which is evaluating the SCD therapy in adult patients with AKI. As of the report, 198 of 339 patients have been enrolled. SeaStar Medical completed the required enrollment in the SAVE Registry, a post-approval surveillance registry for critically ill pediatric patients with AKI and sepsis.
Key figures
- Revenue
- 495
- Total Debt
- 331
- Revenue Yoy
- 69
- Cash Position
- 9348
Price after filing
Close on the filing date to close N calendar days later (from $4.60). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.